Novartis’ Skin Cancer Drug Candidate Fails Late-Stage Trial Target

Novartis AG announced on Saturday that its investigational spartalizumab immunotherapy drug combined with Tafinlar and Mekinist therapies failed to meet its primary endpoint in a late-stage trial for…
Read More